Skip to main content

Table 2 Clinical characteristics of participants

From: Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma

 

Asthma (n = 93)

COPD (n = 116)

Total (n = 209)

Stable /AE status

 AE (%)

10 (10.8)

24 (20.9)

34 (16.3)

 Stable (%)

83 (89.2)

91 (79.1)

174 (83.7)

Newly diagnosed/follow-up patients

Newly-diagnosed (%)

41 (44.1)

36 (31.0)

77 (36.8)

Follow-up (%)

52 (55.9)

80 (69.0)

132 (63.2)

Number of acute exacerbations in the past year

 0 (%)

75 (80.6)

82 (70.7)

157 (75.1)

 1 (%)

10 (10.8)

18 (15.5)

28 (13.4)

 2 (%)

3 (3.2)

7 (6.0)

10 (4.8)

 ≥ 3 (%)

5 (5.4)

9 (7.8)

14 (6.7)

Pulmonary function

 FEV1 (L), mean ± SD

2.3 ± 0.8

1.4 ± 0.6

1.8 ± 0.8

 FEV1, %predicted, mean ± SD

81.5 ± 21.4

51.7 ± 22.0

65.5 ± 26.3

 FEV1/FVC, mean ± SD

74.4 ± 10.9

55.7 ± 11.6

64.3 ± 14.6

 PEF (L), mean ± SD

5.9 ± 1.9

4.0 ± 1.8

4.9 ± 2.1

 IC (L), mean ± SD

2.3 ± 0.6

2.0 ± 0.7

2.1 ± 0.7

 RV/TLC, mean ± SD

43.1 ± 9.0

51.0 ± 9.8

47.3 ± 10.2

GOLD

 I (%)

/

12 (14.5)

/

 II (%)

/

23 (27.7)

/

 III (%)

/

36 (43.4)

/

 IV (%)

/

12 (14.5)

/

Severity of asthma

 Mild and moderate asthma (%)

86 (92.5)

/

/

 Severe asthma (%)

7 (7.5)

/

/

Control of asthma

 Well and partly controlled (%)

83 (89.2)

/

/

 Uncontrolled (%)

10 (10.8)

/

/

 CAT, mean ± SD

/

10.5 ± 6.5

/

 mMRC, mean ± SD

0.4 ± 0.7

1.2 ± 1.0

0.8 ± 0.9

  1. Data are shown as means ± standard deviation or number (%) patients
  2. COPD, chronic obstructive pulmonary disease; AE, acute exacerbation; FEV1, forced expiratory volume in 1 s; FEV1%, FEV1/predicted FEV1; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; PEF, peak expiratory flow; IC, inspiratory capacity; RV/TLC, residual volume/total lung capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease; CAT, COPD Assessment Test; mMRC, Medical Research Council Dyspnea Scale